कृपया अन्य खोज का प्रयास करें
Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing SUBA-Itraconazole, an oral formulation of the drug itraconazole; and conducted a positive Phase 2b study of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Samuel P. Sears | 79 | 2022 | Independent Director |
Ronald E. Osman | 76 | 2023 | Non-Independent Director |
Elizabeth M. Billingsley | - | 2023 | Chairperson of the Scientific Advisory Board |
Niraj Vasisht | 59 | 2022 | Independent Director |
Marc D. Brown | - | 2023 | Member of Scientific Advisory Board |
Sean R. Christensen | - | 2023 | Member of Scientific Advisory Board |
Allison Vidimos | - | 2023 | Member of Scientific Advisory Board |
Michael Jerman | 57 | 2023 | Independent Director |
Michelle Yanez | 51 | 2023 | Director |
Ian Maher | - | 2023 | Member of Scientific Advisory Board |
Francis E. O'Donnell | 74 | 2022 | Founder, Executive Chairman & CEO |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है